Rousselot receives European, Japanese and Chinese patents for Colartix®

"These new patents are a milestone that underscores our commitment and ability to innovate in the collagen industry," said Jeroen Colpaert, Executive Vice President Rousselot. "They do not only provide exclusive protection to our Colartix customers but also strengthen their product appeal to consumers through association with proven innovation and trust."

Backed by scientific research demonstrating its efficacy in alleviating joint discomfort across gender, age and sport intensity¹, Colartix has gained strong market traction since its launch in 2022. Widely incorporated into dietary supplements, it supports both active individuals and those experiencing wear and tear due to aging or excess weight. This demand aligns with the joint health supplement market, which hit $4.4 billion in 2024 and is set to grow 2.4% annually through 2029.²

Colartix is a natural, safe and easy-to-use ingredient, delivering benefits with just 1 gram of daily intake. Its small daily dosage and ability to blend seamlessly with other ingredients make it ideal for a variety of applications, including capsules, powder supplements, tablets and shots.

The European patent, granted by the European Patent Office, is registered under the number EP4465823B1. The Japanese patent, issued by the Japan Patent Office, holds the number JP7690140B2. The Chinese patent, granted by the China National Intellectual Property Administration, is registered under number CN118829360. Patent applications for Colartix are also pending in Brazil and the United States.